A5102733939- Multiple Myeloma Research and Treatments
- CAR-T cell therapy research
- Lung Cancer Treatments and Mutations
- Lymphoma Diagnosis and Treatment
- Cancer Immunotherapy and Biomarkers
- Polyomavirus and related diseases
- Poisoning and overdose treatments
- Cancer Genomics and Diagnostics
- Dental Implant Techniques and Outcomes
- Dental Radiography and Imaging
- Synthesis and Biological Evaluation
- Forensic Toxicology and Drug Analysis
- Periodontal Regeneration and Treatments
- Respiratory and Cough-Related Research
- Pneumonia and Respiratory Infections
- Antibiotic Use and Resistance
- Smoking Behavior and Cessation
- Asthma and respiratory diseases
- Chronic Lymphocytic Leukemia Research
- Monoclonal and Polyclonal Antibodies Research
- Clinical Laboratory Practices and Quality Control
- Blood Pressure and Hypertension Studies
- Ferroptosis and cancer prognosis
- Opioid Use Disorder Treatment
- Nicotinic Acetylcholine Receptors Study
Regeneron (United States)
2021-2024
University College London Hospitals NHS Foundation Trust
2021-2023
University College London
2021-2023
Guy's and St Thomas' NHS Foundation Trust
2019
Pfizer (United States)
2005-2018
Humana (United States)
2013
Varenicline, a selective α4β2 nicotinic acetylcholine receptor partial agonist, is pharmacotherapy indicated for smoking cessation treatment. To our knowledge, no studies have described varenicline treatment adherence and efficacy from real-world patterns in U.S. primary care setting.To estimate to prescription orders subsequent quit rates among smokers setting.In this retrospective cohort study, eligible patients were enrolled with Geisinger Health Plan, had an initial written by provider...
Background: Trends/outcomes associated with National Comprehensive Cancer Network (NCCN)-recommended biomarker testing to guide advanced non-small-cell lung cancer (aNSCLC) treatment were assessed. Methods: Patients initiating first-line aNSCLC included using a nationwide electronic health record-derived database (1/1/2015-10/31/2021). Trends in pre-first-line (PD-L1, major genomic aberrations), factors and associations between outcomes Results: PD-L1/genomic aberration rates increased from...
Methamphetamine is a stimulant drug of abuse with increasing prevalence use worldwide leading to public health concern. While previous research by our group decade ago found no evidence harms associated methamphetamine in the UK, there are conflicting data on whether or not this still case. This paper aims identify trends methamphetamine-related and characterise clinical features ED presentations involving gamma-hydroxybutyrate/gamma-butyrolactone (GHB/GBL).We retrospectively interrogated...
### What you need to know Dizziness is a common presentation emergency departments and primary care.12 It defined as the sensation of disturbed or impaired spatial orientation without false distorted sense motion.3 The estimated prevalence dizziness in general practice community sample varies across studies4 but approximately 20%.56 Its increases with age. While patients often use word “dizziness” describe their symptoms, this encapsulates variety distinct symptom clusters, including vertigo...
Previous audits of antidote stocking in UK hospitals have demonstrated variable but improving compliance with joint Royal College Emergency Medicine and National Poisons Information Service guidance on availability emergency departments. The was updated 2017.To provide a current picture the 2017 compare this to previous audits.Questionnaires were distributed all an department via medicines information regional pharmacy procurement networks. Data collected stock levels category A (immediately...
Topic: 14. Myeloma and other monoclonal gammopathies - Clinical Background: Frontline treatment for multiple myeloma (MM) often utilizes combinations of 2–4 active drugs, including an immunomodulatory drug, a proteasome inhibitor (PI), anti-CD38 antibody (mAb). However, relapse remains persistent problem there is no single algorithm the RRMM. Pomalidomide-based regimens are available in RRMM setting, with those that avoid re-use mAbs assuming greater importance following positioning these...
e23309 Background: BCMA-directed T-cell–engaging therapies have been introduced into clinical practice for the treatment of TCE RRMM. While efficacious, such treatments are associated with safety considerations as cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity (ICANS), and serious infections. These also vary in reported efficacy, administration processes, hospitalization requirements. The aim this study is to quantify patient preferences tradeoffs regarding...
e23310 Background: Chimeric antigen receptor T-cell therapy (CAR T) is FDA-approved in pts with triple-class exposed (TCE) relapsed/refractory (RR) MM after four or more prior lines of (LOTs). Real-world access to CAR T remains challenging due manufacturing capacity, financial barriers, and pt fitness. Pts certain pre-existing comorbidities (e.g., central nervous system disease, heart secondary malignancies) are commonly excluded from clinical trials, including those investigating T. The...
7561 Background: Pts with TCE RRMM have poor outcomes and a high unmet need, no established SOC tx. LINKER-MM1 (NCT03761108) is single-arm, Phase 1/2 study investigating linvoseltamab, B-cell maturation antigen × CD3 bispecific antibody, in pts who were previously treated proteasome inhibitor, immunomodulatory drug, anti-CD38 or triple-class refractory (TCR) to these The aim of this was contextualize by comparing linvoseltamab vs real-world (RW) external control arm (ECA). Methods: A RW ECA...
7560 Background: No head-to-head clinical trials have compared effectiveness of anti-BCMA×CD3 bispecific antibodies for TCE RRMM. This analysis efficacy linvoseltamab vs teclistamab via an unanchored matching-adjusted indirect comparison (MAIC). Methods: A MAIC was deemed feasible after excluding 10 patients (pts) with prior BCMA antibody–drug conjugate exposure from LINKER-MM1 (linvoseltamab) to match MajesTEC-1 (teclistamab) criteria. Pt-level data (107 pts receiving 200 mg in Phase 1/2,...
Aim: To evaluate health-related quality of life (HRQoL) in cemiplimab-treated patients with locally advanced basal cell carcinoma (laBCC).
e19057 Background: In ELM-2 (NCT03888105), a Ph 2, single arm, open label trial, odronextamab demonstrated robust efficacy, generally manageable safety, and overall maintenance of patient-reported outcomes (PROs) in R/R FL pts (Villasboas et al. ASH 2023). FL, with disease progression within 2 yrs frontline chemoimmunotherapy (POD24) are hard to treat poor clinical outcomes, representing an unmet need. We report PROs by POD24 status Grade 1–3a from ELM-2. Methods: Pts received IV 21-day...
9078 Background: Cemiplimab, a PD-1 inhibitor, improved survival and progression-free vs platinum doublet chemotherapy (chemo) in patients (pts) with advanced NSCLC PD-ligand(L)1 expression ≥50% the EMPOWER-Lung 1 Phase 3 study (NCT03088540). Since pts have high symptom burden that adversely impacts QoL functioning, these outcomes were evaluated as secondary endpoints clinical trial. Methods: Pts PD-L1 ECOG performance status ≤1 randomized to IV cemiplimab 350 mg Q3W (n=356) or chemo...